FindMyKOL

Ashish Aneja, MD

Basic profile

MetroHealth

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionCleveland, OH · MidwestSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLFindMyKOL type: NationalLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Ashish Aneja is a Cardiology physician affiliated with MetroHealth. OpenAlex indexes 110 publications with 1,756 citations (h-index 19).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
110publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

1,756citations

Citations across these publications.

19h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • E.R. Squibb & Sons, L.L.C.
    Program year20257 payments
    $10,182
  • Medtronic, Inc.
    Program year20251 payment
    $1,275
  • E.R. Squibb & Sons, L.L.C.
    Program year20246 payments
    $7,024
All 13 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    81.7%
    Beta blocker16.4%
    Metoprolol Succinate67%Metoprolol Tartrate15%Carvedilol10%Atenolol8%
    Part D<11 patients
    Statin12.1%
    Atorvastatin Calcium66%Rosuvastatin Calcium34%
    Part D≥31 patients

    + 12 more classes in this area

  • Blood & clotting

    11.5%
    Factor Xa inhibitor6.6%
    Eliquis67%Xarelto33%
    Part D<11 patients
    P2Y12 inhibitor3.6%
    Clopidogrel100%
    Part D≥11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    6.8%
    SGLT2 inhibitor6.8%
    Farxiga100%
    Part D≥27 patients
Where care is delivered (Part B)95.2% facility · 4.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”